Title:
血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法
Document Type and Number:
Japanese Patent JP2019507866
Kind Code:
A
Abstract:
本発明は、がんに罹患していることが疑われる患者のアフリベルセプトまたはｚｉｖ−アフリベルセプトによる治療の転帰を予測するための、バイオマーカーとしてのＶＣＡＭ−１、ＩＣＡＭ−１および／またはＰｌＧＦの使用に関する。
Inventors:
Mariel Shillon-Blondel
Jennifer Drayman
Caroline Pacard
Jennifer Drayman
Caroline Pacard
Application Number:
JP2018538689A
Publication Date:
March 22, 2019
Filing Date:
January 24, 2017
Export Citation:
Assignee:
SANOFI
International Classes:
G01N33/68; A61K31/4745; A61K31/513; A61K31/519; A61K38/18; A61K47/68; A61P1/00; A61P35/00; A61P35/04; A61P43/00
Domestic Patent References:
| JP2015526430A | 2015-09-10 | |||
| JP2014513089A | 2014-05-29 |
Foreign References:
| WO2016008975A1 | 2016-01-21 | |||
| US20100093552A1 | 2010-04-15 | |||
| US6500633B1 | 2002-12-31 |
Other References:
G.J. BYRNE: "Surrogate markers of tumoral angiogenesis", THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 15, no. 4, JPN6020044994, 2000, pages 334 - 339, ISSN: 0004456061
DIETHER LAMBRECHTS: "Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treate", BRITISH JOURNAL OF CANCER, vol. 113, no. 7, JPN6020044995, 10 September 2015 (2015-09-10), pages 1027 - 1034, XP055283970, ISSN: 0004456062, DOI: 10.1038/bjc.2015.329
問山裕二: "大腸癌患者におけるsoluble-Intercellular adhesion molecule-1(S-ICAM-1)の予後マーカーとしての意義：Duk", 日本臨床外科学会雑誌, vol. 68, JPN6020044996, 5 November 2007 (2007-11-05), pages 394, ISSN: 0004456063
SD FINLEY: "Pharmacokinetics of Anti-VEGF Agent Aflibercept in Cancer Predicted by Data-Driven, Molecular-Detail", PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, vol. 4, no. 11, JPN6020045002, November 2015 (2015-11-01), pages 641 - 649, XP055283961, ISSN: 0004571186, DOI: 10.1002/psp4.12040
CLARE ARNOTT: "The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expr", PLOS ONE, vol. 11, no. 3, JPN6020045005, 9 March 2016 (2016-03-09), pages 0150688, ISSN: 0004571187
MARKUS WEHLAND: "Biomarkers for Anti-Angiogenic Therapy in Cancer", INT. J. MOL. SCI, vol. 4, JPN6020045003, 2013, pages 9338 - 9364, ISSN: 0004571188
YINGMIAO LIU: "Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cance", CANCER MEDICINE, vol. 2, no. 2, JPN6020045004, 2013, pages 234 - 242, ISSN: 0004571189
JOHN F. DE GROOT: "Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept", CLIN CANCER RES, vol. 17, no. 14, JPN6020044997, 2011, pages 4872 - 4881, XP055367887, ISSN: 0004571181, DOI: 10.1158/1078-0432.CCR-11-0271
A. SALMAGGI: "Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) a", CANCER LETTERS, vol. 146, JPN6020044998, 1999, pages 169 - 172, ISSN: 0004571182
朝山雅子: "各臓器がんに対する分子標的治療薬の臨床 大腸がん（Bevacizumab, Cetuximab, Panitumumab, その他）", 月刊腫瘍内科, vol. 4, no. 6, JPN6020044999, 28 December 2009 (2009-12-28), pages 538 - 548, ISSN: 0004571183
JOSEPH BAAR: "A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Ad", CLIN CANCER RES, vol. 15, no. 10, JPN6020045000, 2009, pages 3583 - 3590, XP055284319, ISSN: 0004571184, DOI: 10.1158/1078-0432.CCR-08-2917
ERIC VAN CUTSEM: "Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III", JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 28, JPN6020045001, 1 October 2012 (2012-10-01), pages 3499 - 3506, XP009172937, ISSN: 0004571185, DOI: 10.1200/JCO.2012.42.8201
DIETHER LAMBRECHTS: "Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treate", BRITISH JOURNAL OF CANCER, vol. 113, no. 7, JPN6020044995, 10 September 2015 (2015-09-10), pages 1027 - 1034, XP055283970, ISSN: 0004456062, DOI: 10.1038/bjc.2015.329
問山裕二: "大腸癌患者におけるsoluble-Intercellular adhesion molecule-1(S-ICAM-1)の予後マーカーとしての意義：Duk", 日本臨床外科学会雑誌, vol. 68, JPN6020044996, 5 November 2007 (2007-11-05), pages 394, ISSN: 0004456063
SD FINLEY: "Pharmacokinetics of Anti-VEGF Agent Aflibercept in Cancer Predicted by Data-Driven, Molecular-Detail", PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, vol. 4, no. 11, JPN6020045002, November 2015 (2015-11-01), pages 641 - 649, XP055283961, ISSN: 0004571186, DOI: 10.1002/psp4.12040
CLARE ARNOTT: "The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expr", PLOS ONE, vol. 11, no. 3, JPN6020045005, 9 March 2016 (2016-03-09), pages 0150688, ISSN: 0004571187
MARKUS WEHLAND: "Biomarkers for Anti-Angiogenic Therapy in Cancer", INT. J. MOL. SCI, vol. 4, JPN6020045003, 2013, pages 9338 - 9364, ISSN: 0004571188
YINGMIAO LIU: "Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cance", CANCER MEDICINE, vol. 2, no. 2, JPN6020045004, 2013, pages 234 - 242, ISSN: 0004571189
JOHN F. DE GROOT: "Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept", CLIN CANCER RES, vol. 17, no. 14, JPN6020044997, 2011, pages 4872 - 4881, XP055367887, ISSN: 0004571181, DOI: 10.1158/1078-0432.CCR-11-0271
A. SALMAGGI: "Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) a", CANCER LETTERS, vol. 146, JPN6020044998, 1999, pages 169 - 172, ISSN: 0004571182
朝山雅子: "各臓器がんに対する分子標的治療薬の臨床 大腸がん（Bevacizumab, Cetuximab, Panitumumab, その他）", 月刊腫瘍内科, vol. 4, no. 6, JPN6020044999, 28 December 2009 (2009-12-28), pages 538 - 548, ISSN: 0004571183
JOSEPH BAAR: "A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Ad", CLIN CANCER RES, vol. 15, no. 10, JPN6020045000, 2009, pages 3583 - 3590, XP055284319, ISSN: 0004571184, DOI: 10.1158/1078-0432.CCR-08-2917
ERIC VAN CUTSEM: "Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III", JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 28, JPN6020045001, 1 October 2012 (2012-10-01), pages 3499 - 3506, XP009172937, ISSN: 0004571185, DOI: 10.1200/JCO.2012.42.8201
Attorney, Agent or Firm:
Junji Yuda
Noriyuki Takebayashi
Noriyuki Takebayashi